Immunotherapy in Head and Neck Squamous Cell Cancer
Prognosis in relapsed metastatic head and neck squamous cell cancer (RM-HNSCC) is dismal. Platinum based chemotherapy in combination with Cetuximab is used in first-line setting, while no further validated options are available at progression. Immunotherapy has produced durable clinical benefit in s...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Korean Society of Otorhinolaryngology-Head and Neck Surgery
2018-12-01
|
| Series: | Clinical and Experimental Otorhinolaryngology |
| Subjects: | |
| Online Access: | http://www.e-ceo.org/upload/pdf/ceo-2018-00150.pdf |
| _version_ | 1818133371281211392 |
|---|---|
| author | Nerina Denaro Marco Carlo Merlano |
| author_facet | Nerina Denaro Marco Carlo Merlano |
| author_sort | Nerina Denaro |
| collection | DOAJ |
| description | Prognosis in relapsed metastatic head and neck squamous cell cancer (RM-HNSCC) is dismal. Platinum based chemotherapy in combination with Cetuximab is used in first-line setting, while no further validated options are available at progression. Immunotherapy has produced durable clinical benefit in some patients with RM-HNSCC although the premises are several patients are nonresponders. Studies are ongoing to determine predictive factors and the ideal setting/combination of novel immunotherapies. In this paper, we discuss the past and present of immunotherapy in head and neck cancer and provide an up-to-date information regarding the potential ways to improve immunotherapy outcomes in HNSCC. |
| first_indexed | 2024-12-11T08:51:39Z |
| format | Article |
| id | doaj.art-93278d643b7747c380dcc0838fcaeb5a |
| institution | Directory Open Access Journal |
| issn | 1976-8710 2005-0720 |
| language | English |
| last_indexed | 2024-12-11T08:51:39Z |
| publishDate | 2018-12-01 |
| publisher | Korean Society of Otorhinolaryngology-Head and Neck Surgery |
| record_format | Article |
| series | Clinical and Experimental Otorhinolaryngology |
| spelling | doaj.art-93278d643b7747c380dcc0838fcaeb5a2022-12-22T01:13:59ZengKorean Society of Otorhinolaryngology-Head and Neck SurgeryClinical and Experimental Otorhinolaryngology1976-87102005-07202018-12-0111421722310.21053/ceo.2018.00150584Immunotherapy in Head and Neck Squamous Cell CancerNerina DenaroMarco Carlo Merlano0 Department of Oncology, ASO Santa Croce e Carle, Cuneo, ItalyPrognosis in relapsed metastatic head and neck squamous cell cancer (RM-HNSCC) is dismal. Platinum based chemotherapy in combination with Cetuximab is used in first-line setting, while no further validated options are available at progression. Immunotherapy has produced durable clinical benefit in some patients with RM-HNSCC although the premises are several patients are nonresponders. Studies are ongoing to determine predictive factors and the ideal setting/combination of novel immunotherapies. In this paper, we discuss the past and present of immunotherapy in head and neck cancer and provide an up-to-date information regarding the potential ways to improve immunotherapy outcomes in HNSCC.http://www.e-ceo.org/upload/pdf/ceo-2018-00150.pdfImmunotherapyTumor Immune EscapeSquamous Cell CarcinomaHead And NeckBiomarkers |
| spellingShingle | Nerina Denaro Marco Carlo Merlano Immunotherapy in Head and Neck Squamous Cell Cancer Clinical and Experimental Otorhinolaryngology Immunotherapy Tumor Immune Escape Squamous Cell Carcinoma Head And Neck Biomarkers |
| title | Immunotherapy in Head and Neck Squamous Cell Cancer |
| title_full | Immunotherapy in Head and Neck Squamous Cell Cancer |
| title_fullStr | Immunotherapy in Head and Neck Squamous Cell Cancer |
| title_full_unstemmed | Immunotherapy in Head and Neck Squamous Cell Cancer |
| title_short | Immunotherapy in Head and Neck Squamous Cell Cancer |
| title_sort | immunotherapy in head and neck squamous cell cancer |
| topic | Immunotherapy Tumor Immune Escape Squamous Cell Carcinoma Head And Neck Biomarkers |
| url | http://www.e-ceo.org/upload/pdf/ceo-2018-00150.pdf |
| work_keys_str_mv | AT nerinadenaro immunotherapyinheadandnecksquamouscellcancer AT marcocarlomerlano immunotherapyinheadandnecksquamouscellcancer |